OncoMatch/Clinical Trials/NCT04450173
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
Is NCT04450173 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Obinutuzumab and Ibrutinib for ann arbor stage ii follicular lymphoma.
Treatment: Ibrutinib · Obinutuzumab · Venetoclax — This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating patients with previously untreated stage II-IV follicular lymphoma. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Ibrutinib and venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab, ibrutinib, and venetoclax together may work better in treating follicular lymphoma compared to each drug alone.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage II, III, IV
Grade: 123a
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
Absolute neutrophil count (ANC) > 1.0 x 10^9/L; Platelet count > 50 x 10^9/L; Hemoglobin > 10 g/dL (unless cytopenias due to lymphoma); Prothrombin time (PT)/INR < 1.5 x ULN and PTT (aPTT) < 1.5 x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder; INR <= 3.0 if on warfarin or vitamin K antagonists)
Kidney function
Creatinine clearance > 30 ml/min calculated by modified Cockcroft-Gault formula
Liver function
Serum aspartate transaminase (AST) and alanine transaminase (ALT) < 3 x upper limit of normal (ULN); Bilirubin < 1.5 x ULN unless due to Gilbert's syndrome, documented liver involvement with lymphoma, or of non-hepatic origin, in which case bilirubin should not exceed 3 g/dL
Absolute neutrophil count (ANC) > 1.0 x 10^9/L; Platelet count > 50 x 10^9/L; Prothrombin time (PT)/international normal ratio (INR) < 1.5 x (upper limit of normal) ULN and partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) < 1.5 x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder). When treated with warfarin or other vitamin K antagonists, then INR <= 3.0); Serum aspartate transaminase (AST) and alanine transaminase (ALT) < 3 x upper limit of normal (ULN); Creatinine clearance > 30 ml/min calculated by modified Cockcroft-Gault formula; Bilirubin < 1.5 x ULN unless bilirubin is due to Gilbert's syndrome, documented liver involvement with lymphoma, or of non-hepatic origin, in which case bilirubin should not exceed 3 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco (UCSF) Fresno · Fresno, California
- University of California, Los Angeles · Los Angeles, California
- University of California Davis Comprehensive Cancer Center · Sacramento, California
- University of California, San Diego · San Diego, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify